GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bangkok Genomics Innovation PCL (BKK:BKGI) » Definitions » Intangible Assets

Bangkok Genomics Innovation PCL (BKK:BKGI) Intangible Assets : ฿0.6 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Bangkok Genomics Innovation PCL Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Bangkok Genomics Innovation PCL's intangible assets for the quarter that ended in Sep. 2024 was ฿0.6 Mil.


Bangkok Genomics Innovation PCL Intangible Assets Historical Data

The historical data trend for Bangkok Genomics Innovation PCL's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bangkok Genomics Innovation PCL Intangible Assets Chart

Bangkok Genomics Innovation PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Intangible Assets
0.03 0.20 0.28 1.38 1.08

Bangkok Genomics Innovation PCL Quarterly Data
Dec20 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - 1.08 0.93 0.78 0.63

Bangkok Genomics Innovation PCL Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Bangkok Genomics Innovation PCL  (BKK:BKGI) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Bangkok Genomics Innovation PCL Intangible Assets Related Terms

Thank you for viewing the detailed overview of Bangkok Genomics Innovation PCL's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Bangkok Genomics Innovation PCL Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Scientific testing services which generates key revenue, and Sale of goods.

Bangkok Genomics Innovation PCL Headlines